Information  X 
Enter a valid email address

ShieldTherapeutics Ord1.5P (STX)

Date Time Source Announcement
09 Aug 2022 4:45 pm
RNS
Grant of share options
01 Aug 2022 7:00 am
RNS
Completion of Loan Agreement & Partial Conversion
27 Jul 2022 4:20 pm
RNS
Results of 2022 General Meeting
  4:15 pm
RNS
Results of 2022 Annual General Meeting
26 Jul 2022 7:15 am
EQS
Shield Therapeutics (STX): Looking to accelerate positive signals in the US
14 Jul 2022 7:00 am
RNS
New Drug Submission accepted by Health Canada
08 Jul 2022 7:00 am
RNS
Notice of General Meeting
30 Jun 2022 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:01 am
RNS
2021 Annual Report and 2022 AGM Notice
  7:00 am
RNS
Business Update, Final Results&Financing Agreement
29 Jun 2022 7:00 am
RNS
Notice of Results
28 Jun 2022 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
29 Apr 2022 7:00 am
RNS
Total Voting Rights Update
31 Mar 2022 3:50 pm
RNS
Block Listing Application
  3:50 pm
RNS
Block Listing 6 Monthly Return
21 Mar 2022 7:00 am
RNS
KYE Pharmaceuticals Files Accrufer? NDS in Canada
02 Mar 2022 1:30 pm
EQS
Shield Therapeutics (STX) - PBMs have bought in to Accrufer
25 Feb 2022 7:00 am
RNS
Investor Presentation
23 Feb 2022 2:06 pm
RNS
Second Price Monitoring Extn
  2:01 pm
RNS
Price Monitoring Extension
  11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
18 Feb 2022 2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
17 Feb 2022 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Full Year Trading Update
04 Feb 2022 7:00 am
RNS
KOL Investor Event on Iron Deficiency
07 Jan 2022 7:00 am
RNS
Investor Presentation
05 Jan 2022 7:00 am
RNS
Licence Agreement in Canada for Accrufer?
30 Dec 2021 9:06 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
29 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
16 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Patient Access Expands for Accrufer?
07 Oct 2021 9:45 am
EQS
Shield Therapeutics (STX) Life Sciences Investor Forum research
30 Sep 2021 5:30 pm
RNS
Block Listing 6 Monthly Return
27 Sep 2021 7:00 am
RNS
Jose A. Menoyo Appointed as Chief Medical Officer
21 Sep 2021 7:00 am
RNS
Investor presentation
23 Aug 2021 7:00 am
RNS
PDMR Transaction Notification
20 Aug 2021 11:08 am
EQS
Shield Therapeutics (STX) - Focused on US market penetration
17 Aug 2021 7:00 am
RNS
Half-year Report
12 Aug 2021 7:25 am
EQS
Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum
  7:00 am
RNS
Licence agreement secured in Republic of Korea
11 Aug 2021 7:00 am
RNS
Notice of Results
09 Aug 2021 7:00 am
RNS
AEGIS-CKD study results published in AJKD
04 Aug 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension

a d v e r t i s e m e n t